While observational studies suggested promise, pooled data from controlled trials reveal no benefit.
Mechanical cardiopulmonary resuscitation (CPR) devices showed promise in early observational studies, with evidence of superior perfusion relative to manual CPR. In a meta-analysis, investigators pooled data from 15 observational studies and 5 randomized controlled trials to determine whether mechanical CPR conferred benefit. Outcomes were survival to hospital arrival, survival to hospital discharge, and neurologically intact discharge.
Pooled data from the observational studies suggested a benefit of mechanical ventilation over manual CPR for survival to hospital arrival (odds ratio, 1.42), but pooled data from the controlled trials showed no benefit (OR, 0.94). Neither observational studies nor controlled trials showed a benefit of mechani…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals